BMS-Celgene mega-merger receives shareholder nod 15-Apr-2019 By Ben Hargreaves The $74bn deal appeared to be fraying around edges, as certain shareholders voiced dissent, but a vote saw the deal pass with support from more than 75% of investors.
BMS begins year with $74bn Celgene acquisition 03-Jan-2019 By Ben Hargreaves BMS announced that it will merge with Celgene, bolstering its oncology and immunology/inflammation franchises.